Table 1.
Sample characteristics (sex and age) of patients by cancer site.
| Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|
| Cancer Site | N | <60 | 60–74 | 75+ | N | <60 | 60–74 | 75+ |
| Total | 29841 | 6000 (20.1%) | 13182 (44.2%) | 10659 (35.7%) | 25281 | 7389 (29.2%) | 8415 (33.3%) | 9477 (37.5%) |
| Head and neck | ||||||||
| Larynx | 296 | 73 (24.7%) | 141 (47.6%) | 82 (27.7%) | 72 | 26 (36.1%) | 29 (40.3%) | 17 (23.6%) |
| Oral cavity | 335 | 125 (37.3%) | 143 (42.7%) | 67 (20.0%) | 250 | 75 (30.0%) | 92 (36.8%) | 83 (33.2%) |
| Oropharynx | 497 | 232 (46.7%) | 227 (45.7%) | 38 (7.65%) | 156 | 75 (48.1%) | 62 (39.7%) | 19 (12.2%) |
| Thyroid | 186 | 96 (51.6%) | 64 (34.4%) | 26 (14.0%) | 447 | 322 (72.0%) | 89 (19.9%) | 36 (8.05%) |
| Other head and neck | 305 | 100 (32.8%) | 130 (42.6%) | 75 (24.6%) | 176 | 62 (35.2%) | 63 (35.8%) | 51 (29.0%) |
| Upper gastrointestinal | ||||||||
| Oesophagus | 979 | 185 (18.9%) | 455 (46.5%) | 339 (34.6%) | 412 | 57 (13.8%) | 151 (36.7%) | 204 (49.5%) |
| Stomach | 644 | 120 (18.6%) | 222 (34.5%) | 302 (46.9%) | 385 | 69 (17.9%) | 122 (31.7%) | 194 (50.4%) |
| Lower gastrointestinal | ||||||||
| Anal | 91 | 33 (36.3%) | 34 (37.4%) | 24 (26.4%) | 174 | 63 (36.2%) | 64 (36.8%) | 47 (27.0%) |
| Colon | 2195 | 420 (19.1%) | 750 (34.2%) | 1025 (46.7%) | 2014 | 356 (17.7%) | 585 (29.0%) | 1073 (53.3%) |
| Rectum | 1014 | 236 (23.3%) | 389 (38.4%) | 389 (38.4%) | 627 | 169 (27.0%) | 201 (32.1%) | 257 (41.0%) |
| Small intestine | 132 | 36 (27.3%) | 55 (41.7%) | 41 (31.1%) | 124 | 30 (24.2%) | 44 (35.5%) | 50 (40.3%) |
| Hepato-pancreato-biliary (HPB) | ||||||||
| Liver | 612 | 97 (15.8%) | 297 (48.5%) | 218 (35.6%) | 317 | 52 (16.4%) | 103 (32.5%) | 162 (51.1%) |
| Pancreas | 872 | 150 (17.2%) | 360 (41.3%) | 362 (41.5%) | 853 | 120 (14.1%) | 304 (35.6%) | 429 (50.3%) |
| Other HPB | 174 | 18 (10.3%) | 77 (44.3%) | 79 (45.4%) | 251 | 29 (11.6%) | 84 (33.5%) | 138 (55.0%) |
| Respiratory | ||||||||
| Lung | 3905 | 449 (11.5%) | 1762 (45.1%) | 1694 (43.4%) | 3703 | 454 (12.3%) | 1589 (42.9%) | 1660 (44.8%) |
| Mesothelioma | 393 | 6 (1.53%) | 167 (42.5%) | 220 (56.0%) | 71 | 8 (11.3%) | 24 (33.8%) | 39 (54.9%) |
| Urological | ||||||||
| Bladder | 1104 | 93 (8.42%) | 410 (37.1%) | 601 (54.4%) | 414 | 45 (10.9%) | 124 (30.0%) | 245 (59.2%) |
| Kidney | 1054 | 330 (31.3%) | 453 (43.0%) | 271 (25.7%) | 641 | 170 (26.5%) | 250 (39.0%) | 221 (34.5%) |
| Ureteric and other urinary | 183 | 16 (8.74%) | 96 (52.5%) | 71 (38.8%) | 92 | 7 (7.61%) | 38 (41.3%) | 47 (51.1%) |
| Haematological | ||||||||
| Acute leukaemia | 252 | 68 (27.0%) | 81 (32.1%) | 103 (40.9%) | 219 | 59 (26.9%) | 71 (32.4%) | 89 (40.6%) |
| Chronic lymphocytic leukaemia | 345 | 62 (18.0%) | 168 (48.7%) | 115 (33.3%) | 184 | 21 (11.4%) | 83 (45.1%) | 80 (43.5%) |
| Hodgkin lymphoma | 133 | 83 (62.4%) | 37 (27.8%) | 13 (9.77%) | 110 | 66 (60.0%) | 22 (20.0%) | 22 (20.0%) |
| Multiple myeloma | 537 | 108 (20.1%) | 229 (42.6%) | 200 (37.2%) | 367 | 71 (19.3%) | 138 (37.6%) | 158 (43.1%) |
| Non-Hodgkin lymphoma | 1134 | 294 (25.9%) | 446 (39.3%) | 394 (34.7%) | 921 | 201 (21.8%) | 359 (39.0%) | 361 (39.2%) |
| Other haematological | 360 | 99 (27.5%) | 144 (40.0%) | 117 (32.5%) | 228 | 82 (36.0%) | 82 (36.0%) | 64 (28.1%) |
| Central nervous system (CNS) | ||||||||
| CNS | 452 | 182 (40.3%) | 182 (40.3%) | 88 (19.5%) | 325 | 138 (42.5%) | 99 (30.5%) | 88 (27.1%) |
| Sarcoma | ||||||||
| Bone sarcoma | 42 | 24 (57.1%) | 8 (19.0%) | 10 (23.8%) | 21 | 10 (47.6%) | 5 (23.8%) | 6 (28.6%) |
| Connective and soft tissue sarcoma | 181 | 55 (30.4%) | 64 (35.4%) | 62 (34.3%) | 191 | 66 (34.6%) | 59 (30.9%) | 66 (34.6%) |
| Skin | ||||||||
| Melanoma | 1366 | 441 (32.3%) | 475 (34.8%) | 450 (32.9%) | 1424 | 648 (45.5%) | 454 (31.9%) | 322 (22.6%) |
| Ocular | ||||||||
| Ocular | 57 | 25 (43.9%) | 18 (31.6%) | 14 (24.6%) | 54 | 23 (42.6%) | 16 (29.6%) | 15 (27.8%) |
| Breast | ||||||||
| Breast | 65 | 21 (32.3%) | 25 (38.5%) | 19 (29.2%) | 6101 | 2632 (43.1%) | 1545 (25.3%) | 1924 (31.5%) |
| Gynaecological | ||||||||
| Cervix | - | - | - | - | 252 | 142 (56.3%) | 65 (25.8%) | 45 (17.9%) |
| Ovary | - | - | - | - | 1174 | 419 (35.7%) | 408 (34.8%) | 347 (29.6%) |
| Uterus | - | - | - | - | 1572 | 461 (29.3%) | 718 (45.7%) | 393 (25.0%) |
| Vulva/Vagina | - | - | - | - | 241 | 67 (27.8%) | 73 (30.3%) | 101 (41.9%) |
| Prostate and other male organs | ||||||||
| Penile | 119 | 34 (28.6%) | 58 (48.7%) | 27 (22.7%) | - | - | - | - |
| Prostate | 8747 | 1183 (13.5%) | 4750 (54.3%) | 2814 (32.2%) | - | - | - | - |
| Testicular | 403 | 371 (92.1%) | 27 (6.70%) | 5 (1.24%) | - | - | - | - |
| Other malignant neoplasms | ||||||||
| Other malignant neoplasms | 101 | 41 (40.6%) | 28 (27.7%) | 32 (31.7%) | 89 | 24 (27.0%) | 23 (25.8%) | 42 (47.2%) |
| Unknown primary | ||||||||
| Unknown primary | 576 | 94 (16.3%) | 210 (36.5%) | 272 (47.2%) | 629 | 70 (11.1%) | 177 (28.1%) | 382 (60.7%) |